In a report released today, Serge Belanger from Needham maintained a Buy rating on Collegium Pharmaceutical (COLL), with a price target of $38.00. The company’s shares closed last Monday at $14.68.
According to TipRanks.com, Belanger has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.8% and a 28.7% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Zynerba Pharmaceuticals.
Collegium Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $34.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.59 and a one-year low of $10.01. Currently, Collegium Pharmaceutical has an average volume of 692.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.
